Arylacetamide Deacetylase Enzyme: Presence and Interindividual Variability in Human Lungs

Human arylacetamide deacetylase (AADAC) is a single microsomal serine esterase involved in the hydrolysis of many acetyl-containing drugs. To date, the presence and activity of the AADAC enzyme in human lungs has been scarcely examined. We investigated its gene and protein expression as well as interindividual variations in AADAC activities in a large number of human lungs (n = 25) using phenacetin as a selective substrate. The kinetic parameters Km and Vmax were determined. Our findings highlighted a high interindividual variability in both AADAC mRNA levels and hydrolysis activities. Furthermore, for the first time we demonstrated the presence of the AADAC protein in various lung samples by means of immunoblot analysis. As a comparison, phenacetin hydrolysis was detected in pooled human liver microsomes. Lung activities were much lower than those found in the liver. However, similar Km values were found, which suggests that this hydrolysis could be due to the same enzyme. Pulmonary phenacetin hydrolysis proved to be positively correlated with AADAC mRNA (*P < 0.05) and protein (*P < 0.05) levels. Moreover, the average values of AADAC activity in smokers was significantly higher than in nonsmoker subjects (*P < 0.05), and this might have an important role in the administration of some drugs. These findings add more information to our knowledge of pulmonary enzymes and could be particularly useful in the design and preclinical development of inhaled drugs. SIGNIFICANCE STATEMENT This study investigated the presence and activity of the AADAC enzyme in several human lungs. Our results highlight high interindividual variability in both AADAC gene and protein expression as well as in phenacetin hydrolysis activity. These findings add more information to our knowledge of pulmonary enzymes and could be particularly useful in the design and preclinical development of inhaled drugs.

[1]  Ariel D. Quiroga,et al.  Pharmacological intervention of liver triacylglycerol lipolysis: The good, the bad and the ugly , 2018, Biochemical pharmacology.

[2]  M. Lucchi,et al.  Presence and inter‐individual variability of carboxylesterases (CES1 and CES2) in human lung , 2018, Biochemical pharmacology.

[3]  A. Oda,et al.  Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[4]  T. Fukami,et al.  Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity. , 2016, Biochemical pharmacology.

[5]  T. Fukami,et al.  Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog , 2016, Drug Metabolism and Disposition.

[6]  T. Fukami,et al.  Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  T. Fukami,et al.  Screening of Specific Inhibitors for Human Carboxylesterases or Arylacetamide Deacetylase , 2014, Drug Metabolism and Disposition.

[8]  T. Fukami,et al.  Indiplon Is Hydrolyzed by Arylacetamide Deacetylase in Human Liver , 2014, Drug Metabolism and Disposition.

[9]  Y. Kobayashi,et al.  Species Differences in Tissue Distribution and Enzyme Activities of Arylacetamide Deacetylase in Human, Rat, and Mouse , 2012, Drug Metabolism and Disposition.

[10]  Y. Kobayashi,et al.  Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. , 2011, Biochemical pharmacology.

[11]  Y. Kobayashi,et al.  Arylacetamide Deacetylase Is a Determinant Enzyme for the Difference in Hydrolase Activities of Phenacetin and Acetaminophen , 2010, Drug Metabolism and Disposition.

[12]  T. Fukami,et al.  Human Arylacetamide Deacetylase Is a Principal Enzyme in Flutamide Hydrolysis , 2009, Drug Metabolism and Disposition.

[13]  J. Castell,et al.  Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach. , 2005, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[14]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[15]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[16]  T. Fukami,et al.  The emerging role of human esterases. , 2012, Drug metabolism and pharmacokinetics.